Blood Disorders & Hematology Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

This Phase 3 trial is studying REGN7508, a monoclonal antibody, to prevent blood clots in adults with solid tumors who are undergoing cancer treatment. Blood clots are a serious risk for cancer patients and can lead to dangerous complications. If this treatment works as hoped, it could offer a new way to reduce clotting events and improve the safety of cancer therapy for many patients. The study is currently recruiting adults in the United States and Georgia.

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This Phase 3 trial is testing a new drug combination including glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer. The goal is to see if this new treatment can improve survival compared to the standard therapy with rituximab. The study is actively recruiting adult patients worldwide who have had previous treatments for this condition.

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

This upcoming Phase 3 trial will compare two oral medications, NX-5948 and pirtobrutinib, in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. These patients have not responded to prior treatments targeting a specific protein involved in their cancer. This study could lead to new treatment options once it begins enrolling participants, with plans for 620 adults.

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

This completed Phase 3 trial focused on improving how well children with acute lymphoblastic leukemia take their mercaptopurine medication during remission. Taking the medicine as prescribed is key to preventing relapse. The study enrolled 570 patients across many sites in the US and Puerto Rico and aimed to find better ways to support medication adherence to improve long-term outcomes for young patients.

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years

This Phase 3 trial compared standard drug therapy to high-dose treatment with stem cell transplant in patients up to 65 years old with multiple myeloma. The goal was to determine if high-dose therapy still offers advantages in preventing disease progression now that newer drugs are available. The study completed enrollment of 700 patients in France, and its results will help guide initial treatment decisions for myeloma patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.